Clinical trial NCT01275248: Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder
Official title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder Who Have Not Adequately Responded To Treatment With A Serotonin Reuptake Inhibitor
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Obsessive-compulsive Disorder
Keywords: OCD
Obsessive Compulsive Disorder
Lead sponsor: Transcept Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2011-01-12
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to assess the efficacy and safety of two doses of ondansetron (0.5 mg and 0.75 mg) relative to placebo when administered twice daily as adjunctive therapy for adult patients with Obsessive-Compulsive Disorder (OCD) who have not adequately responded to treatment with a serotonin reuptake inhibitor (SRI).

Detailed description: This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study.

A sufficient number of patients will be screened to obtain approximately 150 patients randomized to the double-blind portion of the study. This study will consist of at least 6 weeks of retrospectively documented SRI treatment (prior to screening), 6 weeks of prospective SRI treatment after screening (run-in) but prior to randomization, and 12 weeks of double-blind treatment with study drug (ondansetron 0.5 mg twice a day, ondansetron 0.75 mg twice a day or placebo twice a day).

All patients will have been maintained on a single SRI at the same dose throughout the retrospective 6-week period and will continue the same SRI at the same dose throughout the run-in and double-blind treatment periods.

The 12-week randomized, double-blind, placebo-controlled, parallel-group study will be the "core period" for purposes of efficacy and short-term safety assessment. Patients completing all 12 weeks of the core period will be offered an opportunity to participate in an "extension period" where they will continue to receive treatment for up to 30 months following the core period.

Treatment assignment in the extension period will be as follows: responders will continue on the same double-blind treatment to which they were assigned in the core period (ondansetron 0.5 mg twice a day, ondansetron 0.75 mg twice a day, or placebo twice a day); non-responders will be reassigned to continuing treatment according to their prior treatment assignment in the core period (those who received placebo will be assigned to ondansetron 0.5 mg twice a day, those who received ondansetron 0.5 mg twice a day will be assigned to ondansetron 0.75 mg twice a day, and those who received ondansetron 0.75 mg twice a day will continue receiving ondansetron 0.75 mg twice a day). Patients will receive treatment under double-blind conditions (double-blind phase of the extension study) until the core study is completed and the safety and efficacy of an ondansetron dose has been confirmed

If after the core study data analysis, no treatment differences are found between ondansetron and placebo in the primary efficacy variable, the extension study will be terminated. If the core study results are positive for the primary efficacy endpoint and safety endpoints, then patients participating in the double-blind phase of the extension study will be offered an opportunity to continue treatment under open-label conditions with the dose deemed efficacious and safe (open-label phase of the extension study). A Data Review Committee will be responsible for reviewing the core study analysis results, providing a dose recommendation for the open-label phase of the extension study, and for communicating the results and their recommendation to the participating institutional review boards/ethics committees (IRBs/ECs) and investigators. Patients may continue receiving treatment for up to 30 months or until the sponsor provides an alternative.

Eligibility criteria: Core period: Inclusion criteria for entry in prospective serotonin reuptake inhibitor (SRI) period (screening):

* Male or female adults 18 years of age or older
* Able to understand the study and provide informed consent
* Subjects who are fluent in English and/or Spanish (speaking, writing, and reading)
* Willing and able to comply with the requirements of the protocol and follow directions from the clinic staff
* Body mass index (BMI) ≤ 40 kg/m\^2 (wearing indoor clothing without shoes)
* For all females: Female patients will be included if they are post-menopausal for at least two years or sterilized, or if they are of childbearing potential, they are not breastfeeding, their pregnancy test is negative, they have no intention of becoming pregnant during the course of the study, and are using adequate contraceptive drugs or devices. Medically acceptable methods of contraception that may be used by the patient and/or her partner are: oral contraceptives, progestin injection or implants, condom with spermicide, diaphragm with spermicide, IUD, vaginal spermicidal suppository, surgical sterilization or abstinence. Females using oral contraception must have started using the medication at least 8 weeks prior to screening. Surgical sterilization must have occurred at least 6 weeks prior to screening.
* Documented diagnosis of Obsessive-Compulsive Disorder (OCD) as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria
* At screening, documented history of stable and current regimen of one of the following five serotonin reuptake inhibitor (SRI) for at least 6 weeks prior to screening at the minimum daily dosage listed:

  * clomipramine (Anafranil®) 150 mg
  * fluvoxamine (Luvox®) 200 mg or fluvoxamine CR (Luvox CR®) 200 mg
  * fluoxetine (Prozac®) 40 mg
  * paroxetine (Paxil®) 40 mg (does not include paroxetine CR (Paxil CR®))
  * sertraline (Zoloft®) 100 mg
* Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of ≥ 24
* Hamilton Depression Rating Scale (HAM-D) score of \< 20

Inclusion criteria for randomization to double-blind treatment period:

* During run-in, documented use of stable and current regimen of one of the following five serotonin reuptake inhibitor (SRI) for at least 6 weeks prior to screening at the minimum daily dosage listed:

  * clomipramine (Anafranil®) 150 mg
  * fluvoxamine (Luvox®) 200 mg or fluvoxamine CR (Luvox CR®) 200 mg
  * fluoxetine (Prozac®) 40 mg
  * paroxetine (Paxil®) 40 mg (does not include paroxetine CR (Paxil CR®))
  * sertraline (Zoloft®) 100 mg
* Demonstrated failure to adequately respond to serotonin reuptake inhibitor (SRI) treatment, defined by the following 2 criteria after 6 weeks of prospective treatment:

  * Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score ≥ 21
  * Less than 25% improvement in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score from Week -6 (screening)
* Hamilton Depression Rating Scale (HAM-D) score of ≤ 16

Extension Period - Inclusion criteria for randomization to double-blind extension treatment period:

* Completing 12 weeks of treatment in the double-blind core period
* Demonstrating compliance in the judgment of the investigator, with both the SRI and study drug as prescribed.

Core Period Exclusion Criteria:

* Presence of significant medical illnesses such as, but not restricted to, cardiovascular, (including congestive heart failure and bradyarrhythmias), endocrine or intestinal disorders that would interfere with the conduct of the study
* History of significant head injury, other significant brain trauma, or seizure disorder (not including a single childhood febrile seizure)
* Clinically significant abnormal laboratory findings. Presence of clinically significant electrolyte abnormalities will be exclusionary.
* Clinically significant abnormal findings on electrocardiogram (ECG). Diagnosis of congenital long QT syndrome will be exclusionary.
* Clinically significant abnormal findings on physical examination
* Positive pregnancy test
* Subjects who intend to donate blood or blood components while receiving study drug or within 1 month of the completion of treatment
* Hoarding as the primary Obsessive-Compulsive Disorder (OCD) symptom (secondary hoarding will be allowed)
* Obsessive-compulsive spectrum disorder as a primary disorder (secondary obsessive-compulsive spectrum disorders will be allowed)
* Requiring active behavioral therapy during the study period (run-in and treatment periods). Patients with a history of behavioral therapy may be enrolled as long as they will not be actively engaged in behavioral therapy during the study. However, booster sessions, occurring no more than quarterly (before and after the core study), are allowed. Supportive and other forms of psychotherapy will be permitted during the study as long as the patient has been engaged in such therapy for at least 8 weeks prior to study enrollment and there are no changes during the study.
* A history of substance dependence or drug or substance abuse, including alcohol abuse, within the past 12 months. A history of nicotine dependence will not be considered an exclusion criterion.
* Mental retardation or an IQ less than 70
* The following comorbid psychiatric conditions identified by current or past medical history or as a result of the Mini-International Neuropsychiatric Interview (MINI) or Structured Clinical Interview for DSM-IV-TR Axis II Personality Disorders (SCID-II) psychiatric interviews will be excluded:

  * Schizophrenia or other psychotic disorders
  * Schizotypal personality disorder
  * Bipolar disorder
  * Gilles de la Tourette syndrome
  * Autism and autistic spectrum disorders
  * Eating disorders
  * Combat-related post-traumatic stress disorder
  * Other comorbid anxiety disorders will be permitted if the severity will not interfere with study participation.
* Subjects who are believed to have suicidal or homicidal risk (i.e., after an assessment by a qualified mental health professional if the C-SSRS screening assessment warranted a suicidal risk assessment interview), or with a history of suicidality in the previous 3 months
* Taking trazodone or other medicinal products that have been associated with prolongation of the QT/QTc interval.
* Taking concomitant antipsychotic drugs, lithium, carbamazepine, oxcarbazepine, phenytoin, anti-anxiety drugs (other than the current SRI for treatment of OCD), or benzodiazepines prescribed for the treatment of anxiety. PRN use of FDA-approved benzodiazepine or non-benzodiazepine hypnotics will be allowed. In addition, the following 3 benzodiazepines will be allowed, provided that patients have been taking them only at bedtime as a sleep aid for at least 12 weeks at the maximum doses noted below:

  * clonazepam (Klonopin®) up to 1 mg
  * diazepam (Valium®) up to 5 mg
  * lorazepam (Ativan®) up to 1 mg
* Taking more than one SRI at the time of screening or at any time in the previous 8 weeks
* A history of having failed more than 2 prior treatments, not including their current course of treatment, with serotonin reuptake inhibitors (SRIs), including clomipramine and selective serotonin reuptake inhibitors (SSRIs), or serotonin-norepinephrine reuptake inhibitors (SNRIs) may only be considered after consultation with the medical monitor. Failure is defined as inadequate response, in the judgment of the treating physician, to an adequate dose of SRIs or SNRIs taken for at least 8 weeks.
* Taking any antidepressant drugs (including St. John's Wort), at the time of screening or at any time in the previous 8 weeks, other than the SRI identified in the retrospective and screening periods
* Likely to use triptans at any time during the run-in or double-blind portion of the trial

Primary outcomes:
measure: Core Period: Change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) total at Month 3 score
timeFrame: Day -1 (baseline), Month 3
measure: Extension Period: Participants with Safety Adverse Experiences
timeFrame: up to Month 33
Secondary outcomes:
measure: Core Period: Participants Considered Responders as Measured by the Clinical Global Impression-Improvement (CGI-I) Score
timeFrame: Month 3
measure: Core Period: Change from Baseline in the Clinical Global Impression-Severity (CGI-S) Score at Month 3
timeFrame: Day -1 (baseline), Month 3
measure: Core Period: Change from Baseline in the Sheehan Disability Scale (SDS) Score at Month 3
timeFrame: Day -1 (baseline), Month 3
Other outcomes:
Locations:
city: Beverly Hills
country: United States
facility: Southwestern Research, Inc.
state: California
city: Imperial
country: United States
facility: Sun Valley Research Center
state: California
city: Los Angeles
country: United States
facility: Pacific Institute for Medical Research
state: California
city: Orlando
country: United States
facility: Compass Research, LLC
state: Florida
city: St. Petersburg
country: United States
facility: University of South Florida
state: Florida
city: Atlanta
country: United States
facility: Emory University
state: Georgia
city: Smyrna
country: United States
facility: Carman Research
state: Georgia
city: Belmont
country: United States
facility: McLean Hospital
state: Massachusetts
city: New Bedford
country: United States
facility: Beacon Clinical Research, LLC
state: Massachusetts
city: Minneapolis
country: United States
facility: Ambulatory Research Center, Dept of Psychiatry
state: Minnesota
city: Berlin
country: United States
facility: Comprehensive Clinical Research
state: New Jersey
city: Bronx
country: United States
facility: Montefiore Medical Center, Child Psychiatry Annex
state: New York
city: Great Neck
country: United States
facility: Biobehavioral Institute, Hofstra
state: New York
city: New York
country: United States
facility: Eastside Comprehensive Medical Center, LLC
state: New York
city: New York
country: United States
facility: Columbia University Medical Center NYS Psychiatric Institute
state: New York
city: Raleigh
country: United States
facility: Richard H. Weisler, MD, PA, and Associates
state: North Carolina
city: Avon Lake
country: United States
facility: Quest Therapeutics of Avon Lake
state: Ohio
city: Mason
country: United States
facility: Lindner Center of HOPE University of Cincinnati
state: Ohio
city: Providence
country: United States
facility: The Body Dysmorphic Disorder (BDD) Program
state: Rhode Island
city: San Antonio
country: United States
facility: Clinical Trials of Texas, Inc
state: Texas
city: Middleton
country: United States
facility: Dean Foundation
state: Wisconsin
city: Milwaukee
country: United States
facility: The Rogers Center for Research and Training
state: Wisconsin
city: Mexico City
country: Mexico
facility: Grupo de Estudios Medicos y Familiares
state: Federal District
city: Mexico City
country: Mexico
facility: Instituto Mexicano de Investigacion Clinica S.A. de C.V. (IMIC)
state: Federal District
city: Leon
country: Mexico
facility: Hospital Aranda de la Parra S.A. de C.V.
state: Guanajuato
city: Guadalajara
country: Mexico
facility: Estudios Integrales en Salud Mental, S.C.
state: Jalisco
city: Monterrey
country: Mexico
facility: CIT Neuropsique
state: Nuevo Leon
city: Monterrey
country: Mexico
facility: Centro par alas Adicciones y Salud Mental S.A.
state: Nuevo Leon
city: Monterrey
country: Mexico
facility: Instituto de Informacion e Investigacion en Salud Mental, A.C. (INFOSAME)
state: Nuevo Leon
city: Tlalnepantla
country: Mexico
facility: Instituto para el Fortalecimiento de Capacidades en Salud
state: State of Mexico
city: Merida
country: Mexico
facility: Instituto para el Fortalecimiento de Capacidades en Salud: Focus Salud Mexico S.C.
state: Yucatan
city: San Luis Potosi
country: Mexico
facility: Hospital Lomas de San Luis Internacional
Study officials:
affiliation: Montefiore Medical Center, Bronx, NY
name: Eric Hollander, MD
role: STUDY_CHAIR
References: